Diabetic Care

Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors Empagliflozin is indicated in: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. To reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and established cardiovascular disease.

This tablet is indicated as an adjunct to diet and exercises to improve glycaemic control in patients with type 2 diabetes mellitus whose diabetes is not adequately controlled on Metformin Hydrochloride or Vildagliptin alone or who are already treated with the combination of Vildagliptin and Metformin Hydrochloride, as separate tablets.

Gliclazide is?ÿindicated for the treatment of non insulin dependent diabetes mellitus (NIDDM) of patients who require oral antidiabetic treatment.

Metformin Hydrochloride is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes. Metformin is also indicated for use in combination therapy with an oral hypoglycemic agent or insulin when diet and exercise does not result in adequate glycemic control.

Metformin Hydrochloride is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes. Metformin is also indicated for use in combination therapy with an oral hypoglycemic agent or insulin when diet and exercise does not result in adequate glycemic control.

Gliclazide is?ÿindicated for the treatment of non insulin dependent diabetes mellitus (NIDDM) of patients who require oral antidiabetic treatment.

This is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both Sitagliptin and Metformin is appropriate.

This is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both Sitagliptin and Metformin is appropriate.

Indications Empagliflozin is indicated in: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. To reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and established cardiovascular disease. Therapeutic Class Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors Pharmacology Empagliflozin is a sodium glucose co-transporter-2 (SGLT-2) inhibitor. SGLT2 co-transporters are…

Glimepiride is indicated as an adjunct to diet to lower the blood glucose in patients with non-insulin-dependent diabetes mellitus (type 2 diabetes) whose hyperglycemia cannot be controlled by diet, physical exercise and weight reduction.Glimepiride is also indicated for use in combination with Insulin to lower blood glucose in patients whose hyperglycaemia can not be controlled by diet and exercise or in conjunction with an oral hypoglycaemic agent.